LillyDirect will help provide services to millions of patients who have yet to be formally diagnosed with the disease.
In the first arrangement of its kind, Eli Lilly to connect patients through telemedicine to providers of Alzheimer’s drugs.
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the treatment's small impact on ...
Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...
Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...
Indianapolis: Indianapolis-based pharmaceutical giant Eli Lilly has faced a setback as the European Union's drug regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback